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Abstract 
Purpose: To determine whether internal limiting membrane (ILM) peeling is effective and 
cost-effective compared with no peeling for patients with idiopathic stage 2 or 3 full-
thickness macular hole (FTMH). 
Methods: Pragmatic, multicenter randomized controlled trial. Eligible participants from nine 
centres were randomized to ILM peeling or no peeling (1:1 ratio) in addition to phaco-
vitrectomy, including detachment and removal of the posterior hyaloid and gas tamponade.  
The primary outcome was distance visual acuity (VA) at six months post-surgery.  Secondary 
outcomes included hole closure, distance VA at other time points, near VA, contrast 
sensitivity,  reading speed,  re-operations, complications, resource use and participant 
reported health status, visual function and costs.   
Results: Of 141 participants randomized in nine centres, 127 (90%) completed six-month 
follow up.  Non-statistically significant differences in distance visual acuity at six-months 
were found between groups [Mean difference 4.8, 95% CI (-0.3, 9.8); p=0.063].  There was a 
statistically significantly higher rate of hole closure in the ILM peel group [56 (84%) versus 
31 (48%)] at one month [Odds ratio (OR):6.23, 95% CI (2.64 to 14.73); p<0.001] with fewer 
re-operations [8 (12%) versus 31 (48%)] performed by six months [OR:0.14, 95% CI (0.05, 
0.34); p<0.001].  Peeling the ILM was likely to be cost-effective.   
Conclusion: There was no evidence of a difference in distance VA following ILM peel and 
no-ILM peel techniques.  An important benefit in favour of no ILM peeling was ruled out.  
Given the higher anatomical closure and lower re-operation rates in the ILM peel group, ILM 
peeling would seem the treatment of choice for idiopathic stage 2-3 FTMH. 
(Clinical Trials.gov number, NCT00286507).
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An idiopathic full-thickness macular hole (FTMH) represents a defect in the area of maximal 
vision of the retina, the fovea; if left untreated often leads to severe central visual loss.1  
FTMH are common, with an estimated incidence of 7.8 persons / 100,000 population per 
year.2  Macular hole surgery, first developed by Kelly and Wendell in 1991,3  represents one 
of the most common procedures performed by vitreo-retinal surgeons.4   
Four stages (1-4) of FTMH have been described;5 randomized controlled clinical 
trials (RCTs) conducted in the 1990s showed that macular hole surgery was effective for 
stages 2, 3 and 4.6,7   
Peeling the internal limiting membrane (ILM) of the retina was introduced as an 
additional manoeuvre in macular hole surgery in order to improve anatomical and functional 
outcomes following surgery.8  Several observational studies suggested a benefit of peeling 
the ILM (reviewed by Abdelkader and Lois9).  Furthermore, recent data from two small 
RCTs undertaken in China and Denmark, which included 49 and 75 patients, respectively, 
suggested a potential beneficial effect of this operation.10,11    
The Full-thickness macular hole and Internal Limiting Membrane peeling Study 
(FILMS), herein reported, was designed as a “pragmatic” RCT to test the hypothesis that 
surgical peeling of the ILM for people with idiopathic FTMH (stages 2 or 3), compared with 
surgery without peel, improves vision, the likelihood of hole closure, participant reported 
health related quality of life and is cost-effective.  “Pragmatic” RCTs aim to determine the 
effects of an intervention under the usual circumstances (i.e. normal clinical practice); as 
opposed to “explanatory” RCTs which are primarily designed to determine the effects of an 
intervention under ideal circumstances. 12 The advantages of a pragmatic design are that if the 
treatment is effective it can be implemented into clinical practice. 
 
Methods 
Study design and eligibility criteria 
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The FILMS study was a multicenter, pragmatic RCT. Patients were enrolled at nine centres, 
seven in UK and two in the Republic of Ireland, by local clinical investigators.  Eligible 
participants were those with stage 2 or 3 idiopathic FTMH of < 18 months duration and 
visual acuity (VA) < 20/40 in the study eye.  At each participating centre, vitreo-retinal 
surgeons followed their usual clinical practice [including slit-lamp biomicroscopy, colour and 
red-free photographs, optical coherence tomography (OCT), fluorescein angiography and 
fundus autofluorescence (AF), as required] to stage FTMH and to confirm eligibility.  
Individuals with stage 1 or 4 FTMH, idiopathic FTMH stages 2-3 of > 18 months duration, 
with other causes of decreased vision, and those with FTMH related to high myopia or 
trauma were excluded.  Individuals that did not understand English and/or unable to give 
informed consent were also excluded. The Medical Research Council Good Clinical Practice 
Guidelines, 1998, and the UK Data Protection Act, 1998 were followed.  Approval by the 
Multicentre Research Ethics Committee, Local Ethics Committees and local hospital trusts of 
each participating centre and participants’ written informed consent were obtained prior to 
the initiation of the study.   
         During the recruitment phase, two RCTs of ILM peeling versus no ILM peeling 
presented their results. 10,11   In light of this, an independent Data Monitoring Committee was 
established (Jan 2007) and reviewed the external and accumulating FILMS trial evidence and 
recommended continuing recruitment.  
        Meetings, involving all individuals participating in this RCT (including vitreo-retinal 
surgeons, optometrists and photographers, in addition to those responsible for the running of 
the trial) were held prior to the initiation of the study to discuss the methodology of this RCT 
and issues regarding data collection.   
 
Study Treatment, randomisation and masking 
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All participants received a combined phacoemulsification and pars plana vitrectomy, 
including detachment and removal of the posterior hyaloid, followed by a fluid-air exchange 
and air-gas [12% perfluoropropane (C3F8)] exchange.  Participants were randomized 1:1 to 
the above procedure alone or combined with ILM peeling using a central telephone IVR 
system at the trial office (Centre for Healthcare Randomised Trials (CHaRT) – UK NIHR 
trials unit.  In the latter, following ILM staining with trypan blue (0.15% trypan blue under 
air for 3 minutes) removal of the ILM  was performed in an area of around 1-2 disc diameters 
around the hole.  Re-staining with trypan blue was permitted at the discretion of the 
vitreoretinal surgeon.  Each vitreo-retinal surgeon judged whether the peeling of the ILM was 
“complete”, as defined by a removal of the ILM all around the hole within a minimal 
extension of 1 disk diameter centred on the centre of the hole or “incomplete” if otherwise.  A 
minimisation algorithm (according to Taves, with P=1)13 was used which allocated treatment 
with respect to minimising imbalance in trial centre, distance vision in the study and fellow 
eye (20/40-20/160; 20/200-20/500; <20/500), stage of the macular hole (2 or 3), duration of 
symptoms (≤1 year; >1 year) and lens status (phakic, aphakic or pseudophakic). Participants 
were followed up at one, three and 6 months post-surgery. 
Further surgical intervention was allowed in either group according to standard 
clinical practice if the macular hole remained opened following surgery, including ILM 
peeling in participants initially randomized to no peel.  All participants were instructed to 
posture face down for a period of five-seven days post-surgery and received a posturing chart 
to record the time postured.   
             Participants and optometrists, who undertook the visual function evaluation of the 
participants, were masked to the treatment allocation.  Vitreo-retinal surgeons, who were 
evaluating the status of the macula hole pre- and post-operatively and performing the surgery 
were, unmasked. 
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Outcomes 
The primary outcome was the mean difference between treatment groups in the Early 
Treatment Diabetic Retinopathy Study (ETDRS) distance VA score at six months.  
Secondary outcomes included ETDRS distance VA at three months, near VA (Bailey-Lovie) 
at three and six months, contrast sensitivity (Pelli-Robson) at six months, reading speed 
(MNRead) at six months, anatomical closure of the macular hole at each time point (one, 
three and six months), participant related outcomes, as determined by the EQ-5D and VFQ-
25 questionnaires, at six months, costs to the health service and the participant, incremental 
costs per quality adjusted life year (QALY) and adverse events.   
The macular hole was considered to be closed when the hole was no longer visible 
clinically (open holes with or without subretinal fluid around them were considered to be 
open).   At each participating centre, vitreo-retinal surgeons followed their usual clinical 
practice [including slit-lamp biomicroscopy, colour and red-free photographs, optical 
coherence tomography (OCT), fluorescein angiography and fundus autofluorescence (AF) as 
required] to determine whether the macular hole was open or closed.  
 
Sample size and statistical analysis 
Assuming a common standard deviation of 12 ETDRS points in the two randomised groups, 
to detect a 6 ETDRS score difference (an effect size of 0.5) using a two sample two sided t-
test at a 5% level of significance and 80% power, it was estimated that 64 participants would 
be required in each group.  This calculation was based on data from published studies.14,15    
The statistical analysis was based on the intention to treat principle: participants 
grouped as randomised irrespective of subsequent compliance.  The primary outcome was 
compared between the two groups using a linear regression model adjusted for the baseline 
score and minimisation covariates. Statistical significance for the primary and secondary 
outcomes were based on two-sided tests with 2P ≤ 0.05 taken as the criterion for statistical 
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significance. The principal analysis was based upon available case data with no imputation of 
missing values. Sensitivity analyses of the primary and macular hole closure outcomes which 
assessed the impact of missing data by imputing extreme values (lowest and highest/open and 
closed respectively) was also undertaken. Additionally, the primary outcome was analysed 
according to the pre-specified subgroups (lens status, duration and stage of the macular hole) 
by including the corresponding interaction term(s) in the regression model using stricter 
criteria for statistical significance (2P ≤ 0.01). Macular hole closure, complications and 
further surgery were analysed using logistic regression model with adjustment for the 
minimisation covariates (except study centre). Analyses of health related quality of life 
measures (EQ-5D and VFQ-25) and secondary measures of visual function (contrast 
sensitivity, reading speed and distance and near visual acuity) were undertaken using linear 
regression adjusted for baseline score in addition to the minimisation variables (bar centre). A 
mean difference was reported for a continuous outcome and an odds ratio (OR) for a binary 
outcome. The corresponding confidence interval (CI) and p-value were reported.  
  
Economic Evaluation 
A cost per participant for each arm of the trial was calculated based upon the use of primary 
and secondary care services.  Resource utilisation per participant was estimated using patient 
questionnaires and information recorded in the three and six month case report forms. Unit 
costs/prices were obtained using information from the National Health Service, published 
estimates for health care services and/or interventions,16-18 as well as study specific estimates.  
QALYs were calculated from responses to the EQ-5D using the area under the curve method 
with EQ-5D responses valued using UK population tariffs.19  Point estimates for mean costs 
and mean QALYs were derived for both ILM peel and no ILM peel groups.  The mean 
difference in costs and QALY were estimated using analysis of covariance adjusting for 
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minimisation factors and baseline EQ-5D for QALYS.  These data were subsequently used to 
estimate an incremental cost per QALY gained.  
The results were presented as point estimates of mean incremental costs, QALYS, and 
incremental cost per QALY.  Measures of variance for these outcomes were estimated by 
bootstrapping costs, QALYs, and incremental cost per QALY.  The incremental cost-
effectiveness data obtained by the bootstrapping exercise were presented in terms of cost-
effectiveness acceptability curves (CEACs).   
 
Further details of the methodology used in FILMS have been published elsewhere.20  As 
stated in this published protocol, in addition to the above, in all participating centres colour 
photographs and red free images were obtained at each time point (baseline, 1, 3 and 6 
months) and evaluated, in a masked fashion and using a computerised programme, to 
objectively determine the size of the hole prior to surgery and the status of the hole post-
operatively.  These data, not presented here, will form part of a separate study evaluating the 
effect of the size of the macular hole on outcomes following surgery.  Furthermore, a long-
term 24 month follow-up evaluation is also included.        
 
Results 
Study Participants  
Between July 1st 2005 and January 31st 2009, 217 patients were approached; of these 76 were 
ineligible (n=44) or declined (n=32) taking part on the study.  One-hundred and forty one 
were eligible, agreed to take part and were randomized (see CONSORT diagram, Figure 1).  
Of these, three were later identified as stage 4 FTMH and therefore were regarded as post-
randomisation exclusions; these were not included in the analyses. Randomized treatment 
groups were generally well balanced with respect to baseline characteristics with the 
exception of gender and EQ-5D scores (Table 1).   
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Surgical details and intraoperative complications 
Table 2 summarizes details of the surgery and intraoperative complications.  More 
participants in the no ILM peel group had surgery performed under general anaesthesia.  On 
average, the surgery took longer if the ILM was peeled than if it was not removed (72.6 
versus 62.6 minutes).  The ILM was completely removed in 64 of 67 participants receiving 
surgery in the ILM peel group; in three participants in this group the ILM was not removed; 
for one participant it was unknown whether they had surgery or not (Figure 1).  Four 
participants in the no ILM peel group received ILM peeling and represented protocol 
deviations though retained in the analyses. No statistically significant differences in the 
number of intraoperative complications were found between groups [38 (57%) versus 28 
(42%) OR: 1.73, 95% CI (0.86, 3.50); p = 0.166].  For both groups, the most common 
intraoperative complication was the occurrence of retinal tears. 
 
Primary and Secondary Outcomes 
No statistically significant differences in distance visual acuity at six months (primary 
outcome) were detected between groups [4.8, 95% CI (-0.3, 9.8); p=0.063] (Table 3).  The 
result was not sensitive to missing data based upon the sensitivity analyses (results not 
shown).  However, an adjusted mean difference of 5 ETDRS letters was observed in favour 
of the ILM peel group. None of the sub-group analyses of the primary outcome were found to 
be statistically significant (data not shown).  No statistically significant differences were 
observed in other functional outcomes at any of the time points studied between groups 
(Table 3). 
 At the one month follow-up visit, macular hole closure was observed in 56 
(84%) participants in the ILM-peel group compared with 31 (48%) in the no ILM peel group; 
this difference was statistically significant [OR: 6.23, 95% CI (2.01, 19.30); p < 0.001]. No 
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statistically significant difference in rates of hole closure between ILM peel and no ILM peel 
groups was observed at three and six months. The sensitivity analysis results for macular hole 
closure did not change the above findings.  A post-hoc subgroup analysis of macular hole 
closure by stage of the hole showed no significant difference [OR: 0.46, 95% CI (0.04, 4.99); 
p = 0.400].  No statistically significant differences in responses to the EQ-5D and VFQ-25 
scores were observed between groups.   
 
Postoperative complications 
No statistically significant differences in the number of complications after initial surgery 
were found between groups [21 (31%) versus 27 (41%); OR: 0.63, 95% CI (0.31, 1.31); p= 
0.218].  Rhegmatogenous retinal detachment occurred in 5% and 3% of cases in ILM peel 
and no ILM peel groups, respectively.  Post-operative complications have been summarized 
in Table 4.  Eight (12%) in the ILM peel group compared with 31 participants (48%) in the 
no ILM peel group required at least one further surgery [OR: 0.14, 95% CI (0.05, 0.34); 
p<0.001] (Table 4).  This difference was driven by 25 (38%) participants in the no ILM peel 
group undergoing peeling of the ILM within the follow-up period. There was one re-opening 
of the macular hole in the no ILM peel group and none in the ILM peel group.  
 
Economic evaluation 
The economic analysis revealed that the mean cost of care was £2550 in the ILM peel group 
and £2974 in the no ILM peel group [difference -£424, 95% CI (-1045, £182)]. The main 
determinant of this difference in mean costs appeared to be the increased need for subsequent 
surgery in the no ILM peel group.  The mean unadjusted QALY scores for each group were 
0.413 in the ILM peel group and 0.438 in the no ILM peel group [difference -0.025, 95% CI 
(-0.424 to 0.452)]. The difference QALYS adjusted for baseline EQ-5D scores and other 
minimisation factors was 0.002 [95% CI (-0.01, 0.013)].  The difference in costs and effects 
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was not statistically significant at the 5% level.  However, based upon the bootstrapped 
estimates of cost-effectiveness it is probable that ILM peeling would be cost-effective at 
typical threshold values for society’s willingness to pay for a QALY (90% chance of being 
considered cost-effective when society’s willingness to pay for a QALY is £20,000). 
 
Discussion 
FILMS found no evidence of a difference between groups in distance visual acuity.  The 
observed difference, which favoured ILM peeling, was however of a clinically relevant 
magnitude (5 ETDRS letters). Furthermore, an important benefit in favour of no ILM peeling 
was ruled out. This, together with the higher rates of macular hole closure and corresponding 
fewer re-operations needed in the ILM peel group suggests that ILM peeling is the treatment 
of choice for patients with stage 2-3 FTMH.  
 Participants randomized to no-ILM peel received ILM peeling if the macular 
hole remained open; this most likely explains the lack of differences in macular hole closure 
rates at three and six months. The difference in the number of re-operations was the main 
driver of differences in cost between the two procedures.  Indeed, the results suggest that 
there is over 90% chance that ILM peeling is less costly than the no peeling technique.  
Importantly, data from this study support a lack of a deleterious effect of ILM peeling in 
visual function, one of the main concerns raised of performing ILM peeling.21  The functional 
and anatomical outcomes achieved in FILMS are consistent with those from two other 
smaller trials comparing macular hole surgery with or without ILM peeling recently 
published.10,11  The benefit of ILM peeling has been also suggested by the results of one other 
RCT very recently completed, which included only participants (n=80) with large holes 
(>400 microns) and which has been published only, to date,  in an abstract form.22   
 Rates of primary hole closure (closure of the hole with a single surgery) of 
84% and 48% achieved in the ILM peel and no ILM peel groups at one month, respectively, 
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in FILMS may seem lower than those reported in previously published observational studies 
(summarized by Abdelkader and Lois).9   Case series, however, are highly prone to selection 
bias and reporting better outcomes than those seen in standard clinical practice.  Most vitreo-
retinal surgeons (>80%) participating in FILMS had extensive experienced in vitreo-retinal 
surgery, including macular hole surgery.  Interestingly, anatomical results in FILMS are 
comparable to those obtained in one of the recently published RCTs with similar inclusion 
criteria, definition for hole closure and surgical protocol than FILMS, in which macular hole 
closure at three months was achieved in 44% and 89% in the no ILM peel group and in the 
trypan-blue assisted ILM group, respectively.10   Thus, it is likely that these lower rates of 
closure are representative of real clinical practice.      
   Cataract surgery was performed in FILMS at the time of the macular hole 
repair.  This would have avoided progression of pre-existing cataracts to act as a possible 
confounder in the evaluation of the functional results.  Furthermore, as complications 
reasonably accredited to the combined procedure seemed to be few and had no deleterious 
effects in vision (Table 5), phaco-vitrectomy for FTMH appears to be a reasonable and 
convenient option for patients and may be a more efficient use of resources.   
 FILMS represents the largest RCT conducted to date aimed to address the 
value of ILM peeling in surgery for idiopathic FTMH and the only one which has included an 
evaluation of the quality of life and cost-effectiveness of the interventions used. Although 
large for the field of Ophthalmology, and specifically, macular hole, this trial may not have 
had enough power to rule out a clinically significant difference in favour of peeling for the 
primary outcome. From a purely scientific viewpoint, the high rate of re-interventions and 
large proportion of participants in the no ILM peel group who subsequently received ILM 
peeling complicates the interpretation of the results. However, it is entirely consistent with 
clinical practice and naturally follows from the intention to treat philosophy as a comparison 
of two intervention pathways.   
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 FILMS randomised 141 participants (90% completed the 6 month follow-up) 
in 9 centres in the UK and Eire. The study was intentionally designed as a pragmatic, as 
opposed to a more explanatory, trial thereby increasing the external validity (generalisability) 
of its findings by reflecting decision making in clinical practice.  Vitreo-retinal surgeons 
determined the diagnosis and staging of FTMH and its status following surgery and the need 
for further surgery based on their own routine clinical practice. Participating surgeons used 
their own routine techniques to induce a posterior hyaloid detachment, to peel the ILM (with 
the exception of the use of trypan blue to stain the ILM) and to achieve an adequate gas 
exchange.  
 In conclusion, data from FILMS suggests that ILM peeling is a safe, clinically 
superior and more cost-effective approach than no ILM peeling to treat patients with 
idiopathic stage 2 or 3 FTMH and, thus, may be considered the treatment of choice for 
patients with this common vitreo-retinal disease.  
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Figure 1: Consort diagram 
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Table 1.  Baseline characteristics 
Participant characteristic    Peel 
 
No peel 
Study eye  – n/N (%)                Right  40/71 (56) 38/66 (58) 
Left  31/71 (44) 28/66 (42) 
Gender – n/N (%) female   56/71 (79) 43/66 (65) 
Age - Median (IQR) years  70, 70.30 
(5.72) 
66, 70.58 
(6.02) 
Duration of symptoms  - N, Mean 
(SD) months 
 71, 7.0 (4.2) 66, 6.5 (4.0) 
Status of lens – n/N (%) Phakic  
Grade Nuclear Standard 
<1 
1 to <3 
3 or more 
Grade PSC Standard  
<1 
1 to <3 
3 or more 
Grade Cortical Standard 
<1 
1 to <3 
3 or more 
 
67/71 (94) 
 
20/64 (31) 
44/64 (69) 
0/64 (0) 
 
48/52 (92) 
4/52 (8) 
0/52 (0) 
 
34/53 (64) 
18/53 (34) 
1/53 (2) 
64/67 (96) 
 
19/60 (32) 
41/60 (68) 
0/60 (0) 
 
43/50 (86) 
6/50 (12) 
1/50 (2) 
 
35/49 (71) 
14/49 (29) 
0/49 (0) 
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 Pseudophakic 4/71 (6) 3/67 (4) 
Stage of macular hole – n/N (%)  
(Clinical classification) 
    
II 29/71 (41) 25/66 (38) 
III 42/71 (59) 41/66 (62) 
EQ-5D  –  N, mean (SD)  65,  
0.80 (0.21) 
63, 
0.88 (0.13) 
VFQ-25 – N, mean (SD)  66, 
79.9 (15.5) 
64, 
80.3 (17.5) 
Distance visual acuity (ETDRS) score 
– N, mean (SD) 
Study eye 71, 
48.1 (13.8) 
66, 
50.0 (10.6) 
Fellow eye 71, 
76.1 (13.5) 
66, 
75.7 (17.1) 
Near visual acuity (Bailey-Lovie) – N, 
mean (SD)) 
Study eye 67, 
0.86 (0.30) 
65, 
0.81 (0.31) 
Fellow eye 67, 
0.32 (0.34) 
64, 
0.27 (0.32) 
Contrast Sensitivity (Pelli-Robson) – 
N, mean (SD) 
Study eye 66, 
30.8 (5.0) 
65, 
30.8 (5.0) 
Reading speed MN Read – N, mean 
(SD) 
Study eye 68, 
137.76 
(55.7) 
64, 
138.6 (48.8) 
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Binocular 66, 
174.4 (44.5) 
63, 
174.2 (45.1) 
 
IQR = interquartile range, PSC = posterior subcapsular cataract, SD=standard deviation, ETDRS = early 
treatment diabetic retinopathy study 
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Table 2.  Surgical details and intra-operative complications 
 
Surgical detail Level Peel 
 
No peel 
Surgeon grade – n/N (%) Consultant 55/67 (82) 51/65 (78) 
 Fellow 12/67 (18) 14/65 (22) 
Assisting surgeon – n/N (%) Consultant 8/67 (12) 10/63 (16) 
 Fellow 10/67 (15) 10/63 (16) 
 Registrar 25/67 (37) 27/63 (43) 
 SHO 4/67 (6) 3/63 (5) 
 Associate  0/67 (0) 1/63 (2) 
 None 20/67 (30) 12/63 (19) 
Type of anaesthesia – n/N (%) General 28/67 (42) 35/65 (54) 
 Local 39/67 (58) 30/65 (46) 
Operation time – N, mean 
(SD) 
Minutes 
      62, 
72.6 (19.0) 
    63, 
62.6 (21.7) 
ILM peeling – n/N (%) 
 
64/67 (96) 4/67 (6%) 
Any intraoperative 
complication* – n/N (%) 
 38/67 (57) 28/65 (43) 
Retinal tears – n/N (%)  18/67 (27) 21/65 (32) 
Retinal detachment – n/N 
(%) 
 4/67 (6) 1/65 (2) 
Retinal haemorrhages – n/N 
(%) 
 13/67 (19) 4/65 (6) 
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Retinal whitening – n/N (%)  9/67 (13) 1/65 (2) 
Choroidal/Suprachoroidal 
haemorrhages – n/N (%) 
 2/67 (3) 0/65 (0) 
Other   7/67 (10) 6/65 (9) 
 
*Some participants had more than one complication 
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Table 3. Primary and secondary outcomes  
Primary outcome  Peel No peel 
Mean diff (95% CI); p-
value 
Distance visual acuity at six 
months; N, mean (SD) 
65, 
61.3 (14.7) 
62, 
59.2 (18.9) 
4.8 (-0.3 to 9.8); 0.063 
Secondary visual outcomes Peel No peel 
Mean diff (95% CI); p-
value 
Distance visual acuity at three 
months; N, mean (SD) 
66, 
59.1 (15.4) 
65, 
56.7 (19.7) 
3.6 (-1.9 to 9.1); 0.201 
Near visual acuity at three 
months; N, mean (SD)  
65, 
0.62 (0.32) 
60, 
0.63(0.38) 
-0.04 (-0.15, 0.06); 0.406 
Near visual acuity at six 
months; N, mean (SD) 
62, 
0.54 (0.31) 
61, 
0.53(0.31) 
-0.03 (-0.12, 0.07); 0.559 
Contrast sensitivity at six 
months; N, mean (SD) 
63, 
31.4 (4.8) 
60, 
32.1(4.2) 
-0.7 (-2.0,  0.7); 0.332 
Reading speed (study eye) at six 
months;  N, mean (SD)  
61,  
168 (53) 
59, 
157(47) 
11 (-3, 26); 0.123 
Reading speed (binocular) at six 
months;  N, mean (SD) 
60, 
188 (44) 
59, 
182(46) 
4 (-7, 14); 0.498 
Secondary outcomes: QOL Peel No peel 
Mean diff (95% CI); p-
value 
EQ-5D six months; N, mean 53, 59, 0.02 (-0.05, 0.08); 0.600 
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(SD) 0.85 (0.20) 0.87 (0.15) 
VFQ-25 six months; N, mean 
(SD) 
55, 
85.7 (11.6) 
59, 
85.8 (13.2) 
0.4 (-3.3, 4.1); 0.847 
Secondary outcome: macular 
hole status – n/N (%)  closed 
Peel   No peel   
Odds ratio (95% CI);p-
value 
one month 
56/67 (84) 31/64 (48) 6.23 (2.64 to 14.73); 
<0.001 
three months 61/66 (92) 52/63 (83) 2.65 (0.84 to 8.36); 0.097 
six months 61/65 (94) 56/63 (89) 1.92 (0.52 to 7.11); 0.330 
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Table 4. Complications and further eye surgery reported during the follow-up (up to six 
months) 
Event – n/N (%) Peel No peel Odds ratio (95% 
CI); p-value 
Any complication*  21/64 (31) 27/62 (44) 0.63 (0.31, 1.31); 
0.218 Anterior uveitis 1/64 (2) 1/62 (2) 
Decentration of the IOL 0/64 (0) 3/62 (5) 
Increased IOP 6/64 (9) 9/62 (15) 
Retinal detachment 3/64 (5) 2/62 (3) 
RPE changes at macula 7/64 (11) 9/62 (15) 
Other 8/64 (13) 6/62 (11) 
Any further eye surgery*   8/67 (12) 31/65 (48) 0.14 (0.05, 0.34); 
<0.001 ILM peel  2/67 (3) 25/65 (38) 
Surgery for retinal detachment  2/67 (3) 2/65 (3) 
Redo macular hole 2/67 (3) 5/65 (8) 
Vitrectomy + gas  2/67 (3) 0/65 (0) 
Yag capsulotomy  0/67 (0) 1/65 (2) 
Removal of oil 1/67 (1) 0/65 (0) 
Epiretinal membrane peel  1/67 (1) 0/65 (0) 
 
* Some participants had more than one complication or further surgery 
